Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1988 2
1991 1
1992 3
1993 4
1994 1
1995 2
1996 2
1997 1
1998 1
1999 1
2000 7
2001 1
2002 8
2003 4
2004 4
2006 4
2007 6
2008 6
2009 7
2010 7
2011 4
2012 11
2013 7
2014 7
2015 12
2016 8
2017 13
2018 9
2019 14
2020 12
2021 9
2022 4
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma"
Page 1
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L. Shustov A, et al. Cancer Treat Res. 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. Cancer Treat Res. 2019. PMID: 30596216 Review.
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recognizes t …
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature …
Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H, Miyagaki T. Kamijo H, et al. Curr Treat Options Oncol. 2021 Jan 7;22(2):10. doi: 10.1007/s11864-020-00809-w. Curr Treat Options Oncol. 2021. PMID: 33415447 Review.
While most patients with early-stage mycosis fungoides (MF) follow an indolent course, patients with advanced-stage MF/Sezary syndrome (SS) have a poor prognosis with a median survival of less than 5 years. ...For cases with blood involvement, mogamulizumab, an anti …
While most patients with early-stage mycosis fungoides (MF) follow an indolent course, patients with advanced-stage MF/Sezary syndrom …
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Sibaud V, et al. Am J Clin Dermatol. 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. Am J Clin Dermatol. 2020. PMID: 32613545 Review.
It also induces an 'off-target' inhibition of a range of other kinases including (but not limited to) epidermal growth factor receptor (EGFR), SRC, and other kinases of the TEC family (interleukin-2-inducible T-cell kinase [ITK], Tec, BMX). Dermatological toxicities …
It also induces an 'off-target' inhibition of a range of other kinases including (but not limited to) epidermal growth factor receptor (EGFR …
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Lancet. 2023 Jun 10;401(10392):1941-1950. doi: 10.1016/S0140-6736(23)00329-X. Epub 2023 Apr 24. Lancet. 2023. PMID: 37105210
BACKGROUND: Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. ...Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sezary syndrome, and at least one poo …
BACKGROUND: Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. …
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Clinical Trial.
BACKGROUND: The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available …
BACKGROUND: The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, a …
Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Lai P, Wang Y. Lai P, et al. Cancer Biol Med. 2021 Feb 15;18(1):34-51. doi: 10.20892/j.issn.2095-3941.2020.0216. Cancer Biol Med. 2021. PMID: 33628583 Free PMC article. Review.
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of skin-homing non-Hodgkin lymphomas. ...These epigenetic regulators are essential in the development of CTCL and provide new insights into the clinical treatments of this refractory disease. …
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of skin-homing non-Hodgkin lymphomas. ...These epigenetic …
Phototherapy of mycosis fungoides.
Trautinger F. Trautinger F. G Ital Dermatol Venereol. 2017 Dec;152(6):597-606. doi: 10.23736/S0392-0488.17.05737-6. Epub 2017 Jul 28. G Ital Dermatol Venereol. 2017. PMID: 28845954 Review.
Mycosis fungoides (MF), the most common variant among cutaneous T cell lymphomas (CTCL), is characterized in its early stages by clonal proliferation of malignant T-cells in the skin manifesting as erythematous patches and plaques with a chronic course …
Mycosis fungoides (MF), the most common variant among cutaneous T cell lymphomas (CTCL), is characterized in its early …
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Argnani L, Broccoli A, Zinzani PL. Argnani L, et al. Cancer Treat Rev. 2017 Dec;61:61-69. doi: 10.1016/j.ctrv.2017.10.007. Epub 2017 Oct 28. Cancer Treat Rev. 2017. PMID: 29102679 Review.
Patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) display a dismal prognosis and their therapy represents an unmet medical need, as the best treatment strategy is yet to be determined. Exciting data on novel targeted a …
Patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) display a dismal prognosis a …
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
Bhurani M, Admojo L, Van Der Weyden C, Twigger R, Bazargan A, Quach H, Zimet A, Coyle L, Lindsay J, Radeski D, Hawkes E, Kennedy G, Irving I, Gutta N, Trotman J, Yeung J, Dunlop L, Hua M, Giri P, Yuen S, Panicker S, Moreton S, Khoo L, Scott A, Kipp D, McQuillan A, McCormack C, Dickinson M, Prince HM. Bhurani M, et al. Leuk Lymphoma. 2021 Feb;62(2):330-336. doi: 10.1080/10428194.2020.1827241. Epub 2020 Oct 7. Leuk Lymphoma. 2021. PMID: 33026266
We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. .. …
We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed …
Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
Querfeld C, Zain J, Rosen ST. Querfeld C, et al. Cancer Treat Res. 2019;176:225-248. doi: 10.1007/978-3-319-99716-2_11. Cancer Treat Res. 2019. PMID: 30596221
Mycosis fungoides and Sezary syndrome are the most common subtypes of all primary cutaneous lymphomas and represent complex diseases that require a multidisciplinary assessment by dermatologists, oncologists, and pathologists. ...However, there is no cure and patients freq …
Mycosis fungoides and Sezary syndrome are the most common subtypes of all primary cutaneous lymphomas and represent complex diseases …
172 results